2022 annual financial data
Gyre Therapeutics 2022 Operating margin
Direct answer
Operating margin was 9%.
Operating income was 9,203,000 CNY and net income was 2,302,000 CNY.
Operating cash flow was 10,677,000 CNY.
Get free Gyre Therapeutics email updates.
Bullstory sends one daily email when new analysis or important company news is available.
Verified data
- Revenue
- 102,290,000 CNY
- Operating income
- 9,203,000 CNY
- Net income
- 2,302,000 CNY
- Operating cash flow
- 10,677,000 CNY